From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA approves Abemaciclib (Verzenio) for advanced hormone receptor-positive breast cancer

from Medscape

The U.S. Food and Drug Administration (FDA) recently approved abemaciclib (Verzenio, Eli Lilly) for the treatment of hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer that has progressed after endocrine therapy. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063